Clinical trial
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of…
NCT00309062 · Allergopharma GmbH & Co. KG, Industry · Completed
Key facts
| NCT number | NCT00309062 |
|---|---|
| Title | Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis |
| Official title | A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1 |
| Lead sponsor | Allergopharma GmbH & Co. KG, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Birch Pollen Allergy |
| Intervention type | Biological |
| Interventions | Recombinant birch pollen |
| Start date | Dec 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2009 |
| First posted | Mar 31, 2006 |
| Last update posted | Mar 11, 2013 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: